Ke Wen Cai
Directeur Général chez Geneception, Inc.
Profil
Amber Cai is a Venture Partner with F-Prime Capital, focusing on early-stage biotechnology investments.
She is the founding CEO of Geneception, a leading gene and cell therapy company.
Prior to joining Geneception, Amber was a founding member of Novartis’ R&D Center in China, where she was most recently the Head of Operations and led the Center’s overall business operations overseeing a broad set of functions.
During 2005-2006, Amber led the efforts to establish Novartis’ R&D presence in China from the concept stage to implementation.
After the Center was established in 2006 as the first fully integrated research and development center in China by multinational pharma companies, she played an instrumental role in recruiting talent, establishing operations, developing Novartis’ China R&D strategy, and building strategic partnerships with government and other external stakeholders and collaborators.
Prior to her work in China, Amber was with the Business Development at Novartis Institutes for BioMedical Researches in Cambridge, MA.
Amber has decades of experience in science before shifting her career into business.
She completed her Ph.D.
at Massachusetts Institute of Technology in GPCR signaling and holds an MBA degree from MIT Sloan School of Management.
Postes actifs de Ke Wen Cai
Sociétés | Poste | Début |
---|---|---|
Geneception, Inc.
Geneception, Inc. BiotechnologyHealth Technology Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA. | Directeur Général | - |
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Private Equity Investor | - |
Skyline Therapeutics (Shanghai) Co., Ltd.
Skyline Therapeutics (Shanghai) Co., Ltd. BiotechnologyHealth Technology Part of Skyline Therapeutics (Hong Kong) Ltd., Skyline Therapeutics (Shanghai) Co., Ltd. is a fully Chinese integrated gene therapy company. The company is based in Shanghai, China. Skyline Therapeutics is dedicated to the discovery, development, and delivery of innovative therapies. The company was founded in 2019. The CEO is Ke Wen Cai. | Directeur Général | - |
Formation de Ke Wen Cai
Massachusetts Institute of Technology | Doctorate Degree |
MIT Sloan School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Finance |
Geneception, Inc.
Geneception, Inc. BiotechnologyHealth Technology Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA. | Health Technology |
Skyline Therapeutics (Shanghai) Co., Ltd.
Skyline Therapeutics (Shanghai) Co., Ltd. BiotechnologyHealth Technology Part of Skyline Therapeutics (Hong Kong) Ltd., Skyline Therapeutics (Shanghai) Co., Ltd. is a fully Chinese integrated gene therapy company. The company is based in Shanghai, China. Skyline Therapeutics is dedicated to the discovery, development, and delivery of innovative therapies. The company was founded in 2019. The CEO is Ke Wen Cai. | Health Technology |